Compare Tango Therapeutics Inc. (TNGX) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs DENTSPLY SIRONA Inc — how do they compare? Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B), while DENTSPLY SIRONA Inc trades at $8.54 (market cap $1.70B). The key difference: Tango Therapeutics Inc. is far larger — about 2.2× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and DENTSPLY SIRONA Inc for 72 Days on average.
| TNGX | XRAY | |
|---|---|---|
Market Cap | $3.75B | $1.70B |
Volume | 9,619,106 | 3,939,845 |
Sector | Health | Health |
52-Week High | $32.90 | $14.68 |
52-Week Low | $7.50 | $8.44 |
Typical Hold Time | 0 Days | 72 Days |
Enterprise Value | $2.77B | $3.77B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
DENTSPLY SIRONA (XRAY) trades at $8.505, down 0.29% and near 52-week lows, with bearish technical signals and mixed fundamentals. The company reported Q2 2026 EPS of $0.52 beating estimates but faces declining revenue and negative margins. Recent news highlights institutional stake increases and ongoing restructuring efforts amid weak dental market conditions.
The stock presents a high-risk opportunity with analyst consensus at $12.50 (47% upside) but requires careful monitoring of margin recovery and sales stabilization. Key risks include persistent net losses, competitive pressures, and execution challenges in the turnaround plan.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
